Supplementary Table S1. Clinical characteristics patients according to BMI, IXE line of treatment, eventual concomitant csDMARD therapy.

Clinical characteristics according to BMI

	Normal weight (36)	Overweight (48)	Obese (36)	p1	p2	p3
Age; mean ± SD	53.4 ± 7.1	53.7 ± 11.9	56.6 ± 8.6	0.45	0.05	0.10
Females; n (%)	24 (66.7)	22 (45.8)	22 (61.1)	0.05	0.62	0.16
Males; n (%)	12 (33.3)	26 (54.2)	14 (38.9)	0.05	0.62	0.16
Smokers; n (%)	10/22 (45.4)	11/28 (39.3)	10/22 (45.4)	0.66	1	0.66
Disease duration (months); mean ± SD	127.8 ± 98.5	109.7 ± 94.4	111.9 ± 75.3	0.22	0.37	0.58
Psoriasis; n (%)	23/32 (71.8)	27/34 (79.4)	27/31 (87.1)	0.47	0.13	0.41
Axial involvement; n (%)	7/29 (24.1)	7/33 (21.2)	6/27 (22.2)	0.78	0.86	0.92
Fibromyalgia; n (%)	7/19 (36.8)	4/26 (15.4)	6/23 (26.1)	0.09	0.45	0.35
Comorbidities; median (IQR)	1 (0-2)	1 (0-2)	1 (0-2)	1	1	1
Glucocorticoids taking; n (%)	11 (30.6)	17 (35.4)	7 (19.4)	0.63	0.27	0.10
Prednisone equivalent dose; mean ± SD	6.8 ± 4.4	6.8 ± 5.8	4.6 ± 1.1	0.48	0.09	0.08
csDMARDs taking; n (%)	21 (58.3)	29 (60.4)	16 (44.4)	0.84	0.23	0.14
IXE first line; n (%)	5 (13.9)	14 (29.2)	9 (25)	0.09	0.23	0.67
IXE second line; n (%)	10 (27.8)	10 (20.8)	8 (22.2)	0.45	0.63	0.82
IXE third or more line; n (%)	21 (58.3)	24 (50)	19 (52.8)	0.13	0.17	0.80

Clinical characteristics according to IXE line of treatment

	IXE 1st line (54)	IXE 2nd line (60)	IXE > 2nd line (109)	p1	p2	p3
Age; mean ± SD	54.9 ± 12	59.6 ± 8.9	55.7 ± 10.2	0.37	0.33	0.47
Females; n (%)	24 (44.4)	29 (48.3)	73 (66.9)	0.67	0.01	0.005
Males; n (%)	30 (55.6)	31 (51.7)	36 (33.1)	0.67	0.01	0.005
Smokers; n (%)	10/20 (50)	10/25 (40)	26/62 (41.9)	0.50	0.52	0.86
BMI normal weight; n (%)	3/28 (10.7)	10/28 (35.7)	21/64 (32.8)	0.02	0.02	0.78
BMI overweight; n (%)	14/28 (50)	10/28 (35.7)	24/64 (37.5)	0.28	0.26	0.87
BMI obese; n (%)	9/28 (32.1)	8/28 (28.6)	19/64 (29.7)	0.77	0.93	0.84
Disease duration (months); mean ± SD	60.2 ± 84.9	125.5 ± 109.2	139.8 ± 75.2	0.01	<0.0001	0.21
Psoriasis; n (%)	26/33 (78.8)	35/46 (76.1)	69/85 (81.2)	0.77	0.76	0.49
Axial involvement; n (%)	6/24 (25)	7/44 (15.9)	22/82 (26.8)	0.36	0.85	0.16
Fibromyalgia; n (%)	5/30 (16.7)	9/37 (24.3)	17/59 (28.8)	0.44	0.20	0.63
Comorbidities; median (IQR)	1 (0-2)	1 (0-2)	1 (0-2)	1	1	1
Glucocorticoids taking; n (%)	11 (20.4)	13 (21.6)	31 (28.4)	0.86	0.26	0.33
Prednisone equivalent dose; mean ± SD	7.7 ± 6.9	6.2 ± 4.2	7.6 ± 5.9	0.24	0.46	0.15
csDMARDs taking; n (%)	29 (53.7)	18 (30)	49 (44.9)	0.01	0.29	0.05

Clinical characteristics according to concomitant csDMARD therapy

	IXE (127)	IXE + csDMARD (96)	*p*-value
Age; mean ± SD	55.8 ± 11.3	55 ± 9	0.58
Females; n (%)	70 (55.1)	56 (58.3)	0.63
Males; n (%)	57 (44.9)	40 (41.7)	0.63
Smokers; n (%)	26/60 (50)	20/47 (42.6)	0.93
BMI normal weight; n (%)	15/54 (27.8)	21/66 (31.8)	0.59
BMI overweight; n (%)	19/54 (35.2)	29/66 (43.9)	0.33
BMI obese; n (%)	20/54 (37)	16/66 (24.3)	0.12
Disease duration (months); mean ± SD	139.9.2 ± 94.9	101 ± 75.9	0.01
Psoriasis; n (%)	83/102 (81.4)	47/62 (75.8)	0.39
Axial involvement; n (%)	22/94 (23.4)	13/56 (23.2)	0.97
Fibromyalgia; n (%)	18/75 (24)	13/51 (25.5)	0.84
Comorbidities; median (IQR)	1 (0-2)	1 (0-2)	1
Glucocorticoids taking; n (%)	24 (18.9)	31 (32.3)	0.02
Prednisone equivalent dose; mean ± SD	5.7 ± 3.2	7.6 ± 6.9	0.16
Ixekizumab first line; n (%)	25 (19.7)	29 (30.2)	0.06
Ixekizumab second line; n (%)	42 (33.1)	18 (18.8)	0.01
Ixekizumab third or more line; n (%)	60 (47.2)	49 (51)	0.57

SD: standard deviation; BMI: Body Mass Index; IQR: interquartile range; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs; IXE: ixekizumab.
p1 resulted from comparison of second and third columns, p2 resulted from comparison of second and fourth columns, and p3 resulted from comparison of third and fourth columns.

Supplementary Table S2. Therapeutic effectiveness in patients stratified according to BMI, IXE line of treatment, eventual concomitant csDMARD therapy.

Therapeutic effectiveness according to BMI

	Normalweight			Overweight			Obese			
	T0 (36)	T6 (23)	T12 (12)	T0 (48)	T6 (30)	T12 (17)	T0 (36)	T6 (23)	T12 (15)	*p*-value
DAPSA; mean ±SD	22.5 ± 3.2	16.1 ± 10.3	10.2 ± 7	20.8 ± 1.56	11.9 ± 8.2	9.5 ± 6.1	20.8 ± 0.3	13.7 ± 7	16.4 ± 9.8	0.06
ΔDAPSA; mean ± SD	-	-0.3 ± 9.9	-5.7 ± 12.1	-	-2.7 ± 8.9	-2.4 ± 8.5	-	-2.7 ± 8.9	-0.1 ± 9.9	0.89
PASI; mean ± SD	2 ± 3.6	0.9 ± 1.7	0.6 ± 1.6	3 ± 3.8	1.7 ± 2.7	1 ± 1.9	3.9 ± 5.2	1.7 ± 2.7	1.1 ± 3.1	0.48
ΔPASI; mean ± SD	-	-0.2 ± 2.8	-1.3 ± 2.4	-	-0.9 ± 5.4	-2.9 ± 4.8	-	-0.9 ± 5.4	-1.2 ± 3.1	0.17
TJC; mean ± SD	3.4 ± 6.7	2 ± 4.3	1.2 ± 2.3	2.7 ± 4.7	1.2 ± 2.6	0.9 ± 2	3.1 ± 4.5	1.2 ± 2.6	2.5 ± 5.1	0.05
SJC; mean ± SD	1 ± 2.3	0.6 ± 2.4	0.1 ± 0.4	0.9 ± 2.1	0.7 ± 1.7	0.3 ± 0.7	0.7 ± 1.5	0.7 ± 1.7	0.8 ± 2.3	0.15
VAS pain; mean ± SD	62.5 ± 23.1	49.1 ± 28.1	36.3 ± 32	61.8 ± 26.9	42.9 ± 29.3	34.7 ± 27.2	61.1 ± 21.9	42.9 ± 29.3	46 ± 20.6	0.32

Therapeutic effectiveness according to IXE line of treatment

	IXE 1st line			IXE 2nd line			IXE > 2nd line			
	T0 (54)	T6 (25)	T12 (17)	T0 (60)	T6 (37)	T12 (17)	T0 (109)	T6 (72)	T12 (43)	*p*
DAPSA; mean ± SD	16.4 ± 8.4	10.8 ± 7.1	8.5 ± 5.7	20.8 ± 12.8	11.3 ± 6.3	15.4 ± 8.9	21.8 ± 12	8.6 ± 8.1	14.5 ± 12.2	0.15
ΔDAPSA; mean ± SD	-	-5 ± 9.3	-7.6 ± 9.9	-	-4.2 ± 8.7	-5 ± 9.1	-	-8.5 ± 10.7	-6.8 ± 9.2	0.64
PASI; mean ± SD	2.4 ± 4.7	0.4 ± 2.5	0.6 ± 1.9	3.2 ± 5.5	1.3 ± 2	0.6 ± 1.4	2.2 ± 3.6	0.4 ± 2.1	0.8 ± 2.8	0.50
ΔPASI; mean ± SD	-	-0.2 ± 2.6	-0.5 ± 2.6	-	-3.4 ± 5.1	-1.8 ± 4.2	-	-2.3 ± 4.2	-1.6 ± 3.7	0.55
TJC; mean ± SD	3.9 ± 3.2	2.7 ± 3.6	1.7 ± 2	3.6 ± 7.2	3.4 ± 4	3.8 ± 4.3	3.6 ± 6.5	2.2 ± 2.8	4 ± 3.6	0.24
SJC; mean ± SD	1.7 ± 2	0.7 ± 0.9	0.3 ± 0.4	1.8 ± 1.9	0.3 ± 0.6	1.1 ± 1.6	1.4 ± 1.9	0.3 ± 0.3	0.7 ± 1.4	0.93
VAS pain; mean ± SD	54.5 ± 25.6	32.4 ± 28.9	28.7 ± 24	58.1 ± 23.4	46.2 ± 24.5	49.2 ± 26.1	53.1 ± 23.6	29.4 ± 26.6	49.6 ± 31.4	0.24

Therapeutic effectiveness according to concomitant csDMARD therapy

	IXE			IXE + csDMARD			
	T0 (127)	T6 (81)	T12 (43)	T0 (96)	T6 (53)	T12 (34)	*p*
DAPSA; mean±SD	11.1 ± 11.6	7.9 ± 8.1	7.6 ± 6.1	12.3 ± 11.8	11.2 ± 7	5.7 ± 5.9	0.68
ΔDAPSA; mean ± SD	-	-0.9 ± 9.6	-2.6 ± 11	-	-0.8 ± 9.3	-2.3 ± 9.6	0.96
PASI; mean ± SD	2.5 ± 3.5	1 ± 2	0.6 ± 1.4	2.5 ± 5.3	1.5 ± 2.5	1.4 ± 2.6	0.09
ΔPASI; mean ± SD	-	-0.5 ± 5	-1.2 ± 4.1	-	-0.1 ± 4.4	-2.7 ± 4.6	0.55
TJC; mean ± SD	3.3 ± 6.6	1.9 ± 4.2	1.4 ± 3.2	3.2 ± 5.7	1.6 ± 3.6	1.5 ± 1.2	0.32
SJC; mean ± SD	0.6 ± 1.9	0.3 ± 1.6	0.1 ± 0.4	1 ± 2.4	0.5 ± 1.3	0.4 ± 0.6	0.20
VAS pain; mean ± SD	57 ± 24.8	44.5 ± 25.8	35.8 ± 27.5	63.8 ± 21.4	45.9 ± 26.3	29.1 ± 25.1	0.56

DAPSA: disease activity in psoriatic arthritis; SD: standard deviation; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; PASI: Psoriasis Area Severity Index; TJC: tender joint count; SJC: swollen joint count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; VAS: visual analogue scale; PtGA: patients global assessment; PhGA: physician global assessment; BMI: Body Mass Index; IXE: ixekizumab; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs.